TN2014000418A1 - Methods for treating cancer using pi3k inhibitor and mek inhibitor - Google Patents

Methods for treating cancer using pi3k inhibitor and mek inhibitor

Info

Publication number: TN2014000418A1
Authority: TN; Tunisia
Prior art keywords: inhibitor; methods; treating cancer; mek; pi3k
Prior art date: 2012-04-06

Application number

TN2014000418A

Other languages

English (en)

Inventor

Karl Hsu

Joanne Lager

Janet Anne Meurer Ogden

Original Assignee

Sanofi Sa

Merck Patent Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-04-06

Filing date

2014-10-02

Publication date

2016-03-30

2014-10-02 Application filed by Sanofi Sa, Merck Patent Gmbh filed Critical Sanofi Sa

2016-03-30 Publication of TN2014000418A1 publication Critical patent/TN2014000418A1/fr

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Reproductive Health (AREA)
Pulmonology (AREA)
Gynecology & Obstetrics (AREA)
Pregnancy & Childbirth (AREA)
Endocrinology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

TN2014000418A 2012-04-06 2014-10-02 Methods for treating cancer using pi3k inhibitor and mek inhibitor TN2014000418A1 (en)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US201261621252P	2012-04-06	2012-04-06
FR1351158		2013-02-12
US201361771457P	2013-03-01	2013-03-01
PCT/US2013/035231 WO2013152165A1 (fr)	2012-04-06	2013-04-04	Méthodes de traitement du cancer à l'aide d'un inhibiteur de pi3k et d'un inhibiteur de mek

Publications (1)

Publication Number	Publication Date
TN2014000418A1 true TN2014000418A1 (en)	2016-03-30

Family

ID=49301040

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TN2014000418A TN2014000418A1 (en)	2012-04-06	2014-10-02	Methods for treating cancer using pi3k inhibitor and mek inhibitor

Country Status (18)

Country	Link
US (1)	US20150031882A1 (fr)
EP (1)	EP2854854A1 (fr)
JP (1)	JP2015515476A (fr)
KR (1)	KR20150003786A (fr)
CN (1)	CN104334192A (fr)
AU (1)	AU2013243429A1 (fr)
CA (1)	CA2869152A1 (fr)
CL (1)	CL2014002668A1 (fr)
CO (1)	CO7121349A2 (fr)
CR (1)	CR20140480A (fr)
DO (1)	DOP2014000221A (fr)
EA (1)	EA201491836A1 (fr)
MX (1)	MX2014012001A (fr)
PE (1)	PE20142020A1 (fr)
PH (1)	PH12014502219A1 (fr)
SG (1)	SG11201406199TA (fr)
TN (1)	TN2014000418A1 (fr)
WO (1)	WO2013152165A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2015095829A1 (fr)	2013-12-20	2015-06-25	Biomed Valley Discoveries, Inc.	Traitements du cancer a l'aide des combinaisons de la voie pi3k/akt et d'inhibiteurs de erk
JP6745048B2 (ja) *	2015-10-14	2020-08-26	日東紡績株式会社	２種のプロテインキナーゼの活性測定を用いる解析方法による、薬剤感受性ヒト細胞株の判定方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7956191B2 (en)	2004-10-20	2011-06-07	Merck Serono Sa	3-arylamino pyridine derivatives
US8044062B2 (en) *	2005-10-07	2011-10-25	Exelixis, Inc.	Substituted pyrido[2,3-d]pyrimidin-7(8H)-one inhibitors of phospatidylinositol 3-kinase alpha
UA116188C2 (uk)	2005-10-07	2018-02-26	Екселіксіс, Інк.	Інгібітори фосфатидилінозит-3-кінази і способи їх застосування
US20110086837A1 (en) *	2009-10-12	2011-04-14	Genentech, Inc.	Combinations of a pi3k inhibitor and a mek inhibitor
AR084216A1 (es) *	2010-12-09	2013-05-02	Sanofi Sa	Composiciones y metodos para tratar el cancer usando un inhibidor de pi3k e inhibidor de mek, kit

2013
- 2013-04-04 CA CA2869152A patent/CA2869152A1/fr not_active Abandoned
- 2013-04-04 MX MX2014012001A patent/MX2014012001A/es unknown
- 2013-04-04 WO PCT/US2013/035231 patent/WO2013152165A1/fr not_active Ceased
- 2013-04-04 JP JP2015504716A patent/JP2015515476A/ja active Pending
- 2013-04-04 SG SG11201406199TA patent/SG11201406199TA/en unknown
- 2013-04-04 CN CN201380029317.1A patent/CN104334192A/zh active Pending
- 2013-04-04 KR KR20147030877A patent/KR20150003786A/ko not_active Withdrawn
- 2013-04-04 EA EA201491836A patent/EA201491836A1/ru unknown
- 2013-04-04 AU AU2013243429A patent/AU2013243429A1/en not_active Abandoned
- 2013-04-04 PE PE2014001533A patent/PE20142020A1/es not_active Application Discontinuation
- 2013-04-04 EP EP13717123.7A patent/EP2854854A1/fr not_active Withdrawn
2014
- 2014-10-01 DO DO2014000221A patent/DOP2014000221A/es unknown
- 2014-10-01 PH PH12014502219A patent/PH12014502219A1/en unknown
- 2014-10-02 US US14/504,970 patent/US20150031882A1/en not_active Abandoned
- 2014-10-02 TN TN2014000418A patent/TN2014000418A1/fr unknown
- 2014-10-03 CL CL2014002668A patent/CL2014002668A1/es unknown
- 2014-10-16 CR CR20140480A patent/CR20140480A/es unknown
- 2014-10-29 CO CO14239743A patent/CO7121349A2/es not_active Application Discontinuation

Also Published As

Publication number	Publication date
JP2015515476A (ja)	2015-05-28
WO2013152165A1 (fr)	2013-10-10
DOP2014000221A (es)	2014-12-15
AU2013243429A1 (en)	2014-10-23
CR20140480A (es)	2014-11-17
MX2014012001A (es)	2015-05-11
PH12014502219A1 (en)	2015-01-12
CN104334192A (zh)	2015-02-04
CL2014002668A1 (es)	2015-01-16
SG11201406199TA (en)	2014-10-30
EA201491836A1 (ru)	2015-02-27
CO7121349A2 (es)	2014-11-20
EP2854854A1 (fr)	2015-04-08
US20150031882A1 (en)	2015-01-29
CA2869152A1 (fr)	2013-10-10
KR20150003786A (ko)	2015-01-09
PE20142020A1 (es)	2014-12-24

Publication	Publication Date	Title
TN2013000508A1 (en)	2015-03-30	Combination therapy comprising a cdk4/6 inhibitor and a pi3k inhibitor for use in the treatment of cancer
MX2020004689A (es)	2021-07-09	Tratamiento del cancer con inhibidores de tor cinasa.
PH12014502048B1 (en)	2020-10-28	Treatment of cancer with tor kinase inhibitors
PH12016500768B1 (en)	2016-06-20	Methods of treating and preventing graft versus host disease
PH12014502029A1 (en)	2014-11-24	Treatment of cancer with tor kinase inhibitors
MX2014012477A (es)	2014-12-10	Inhibidores pirrolopirazona de tanquirasa.
PH12014502046A1 (en)	2014-12-10	Treatment of cancer with tor kinase inhibitors
CA2908742C (fr)	2021-06-01	Polytherapie comprenant un inhibiteur de la kinase tor et un analogue de la cytidine pour le traitement du cancer
MX2014000150A (es)	2014-05-14	Sistemas, metodos y formulaciones para tratamiento de cancer.
PH12013501163A1 (en)	2013-07-29	Compositions comprising a p13k inhibitor and a mek inhibitor and their use for treating cancer
PH12015500867A1 (en)	2015-06-22	Treatment of prostate cancer with tor kinase inhibitors
TN2014000418A1 (en)	2016-03-30	Methods for treating cancer using pi3k inhibitor and mek inhibitor
UY35033A (es)	2014-04-30	Formulación en comprimidos de un inhibidor de la fosfatidilinositol 3-cinasa
PH12014500973A1 (en)	2014-06-16	Phosphatidylinositol 3-kinase inhibitors for the treatment of lymphoproliferative malignancies
TN2013000247A1 (en)	2014-11-10	Compositions comprising a pi3k inhibitor and a mek inhibitor and their use for treating cancer
CO6721062A2 (es)	2013-07-31	Cmposiciones y métodos para tratar el cancer usando un inhibidor de pi3k y un inhibidor de mek
ECSP13012736A (es)	2013-09-30	Composiciones y métodos para tratar el cáncer usando un inhibidor de pi3k y un inhibidor de mek
NI201300052A (es)	2013-11-12	Composiciones y métodos para tratar el cáncer usando un inhibidor de pi3k y un inhibidor de mek
GT201300148A (es)	2014-08-05	Composiciones y métodos para tratar el cáncer usando un inhibidor de p13k y un inhibidor de mek